Consortium launches ambitious project to transform the treatment of pain – News-Medical.net

In an effort to address the critical public health need for new, safer and more effective medicines to treat pain, a consortium based at the Laboratory of Systems Pharmacology (LSP) at Harvard Medical School has launched an ambitious project titled STOP PAIN (Safe Therapeutic Options for Pain and Inflammation).

By combining a wide range of experimental and artificial intelligence-driven approaches, the consortium aims to identify compounds that selectively block the activity of nociceptors--the sensory neurons that sense and initiate pain--with the goal of developing new, preclinical drug candidates that offer an alternative to the opioid-based medications at the heart of the U.S. opioid epidemic.

The project is led by researchers from HMS and Boston Children's Hospital, with collaborators from Massachusetts Institute of Technology (MIT) and the Max Planck Institute for Medical Research in Germany.

It is supported by the U.S. Defense Advanced Research Projects Agency (DARPA) through the Panacea program, which aims to engender new therapies that address under-met medical needs of active duty soldiers and veterans. The DARPA cooperative agreement includes funding of up to $23,378,281.

The STOP PAIN consortium encompasses expertise across research disciplines, including neurobiology, systems pharmacology, stem cell biology, and computational and medicinal chemistry, and is led by:

We have substantial opportunities today to combine new laboratory methods, advanced chemistry and artificial intelligence and bring those tools to bear on the enormous societal, scientific and medical challenges of pain management.

Modern cancer care, for example, is now full of promising new medicines based on transformative science, yet if we look back two decades the field appeared to be stuck. We hope that advances in the science of sensation and computing will similarly shift the trajectory of drug development for pain."

Peter Sorger

According to the National Institute on Drug Abuse, an estimated 1.7 million Americans suffered from substance use disorders related to prescription opioid pain relievers in 2017 alone, and more than 47,000 died as a result of opioid overdose, leading government agencies to declare a nationwide public health emergency that year.

Prescription opioids are generally effective for the immediate and temporary treatment of severe pain, such as after trauma or surgery. However, they are only partially or not at all effective for chronic pain, and their prolonged use carries serious risks for developing tolerance, addiction and misuse.

Efforts to develop nonopioid pain therapies have been largely unsuccessful, highlighted, for example, by the high-profile recall of the prescription pain and inflammation drug Vioxx in 2014. Currently available medications such as acetaminophen and ibuprofen are not as effective as opioids and, when used long-term, can have adverse side effects that include gastrointestinal bleeding and liver damage.

Due to the lack of viable alternatives, prescription opioids remain a primary therapeutic option for the management of both acute and chronic pain.

"If we can successfully build better drugs to control pain, such that no physician would ever need to prescribe opioids because there would be safer and more effective options available, there would be an enormous impact on both the practice of medicine and on the societal catastrophe that the opioid epidemic has created," Woolf said. "As a consortium, we are keen to accept this challenge and to do everything possible to achieve this goal."

To identify new, nonopioid drug candidates, the STOP PAIN consortium is taking a unique approach that embraces the complexity of the biology of pain.

Current drug development processes in industry typically focus on screening for compounds that affect a single biological target--such as recent failed efforts to develop drugs targeting the protein Nav1.7, identified as defective in people with a congenital disorder that renders them insensitive to pain.

In contrast, the consortium will not begin with predetermined targets but instead focus on the activity of cells, specifically the nociceptor neurons responsible for initiating the sensation of pain.

"This project is based on the recognition that many of the most effective drugs for other neurological diseases have many molecular targets, not just one," Bean said. "Our goal is to systematically understand the complex network of molecules controlling the function of pain-sensing neurons and use that knowledge to design drug molecules that hit many targets, with the aim of safely and selectively inhibiting nociceptor function."

The team will screen for small molecule, nonopioid-based compounds that silence the activity of stem-cell derived human nociceptors under laboratory conditions.

The team will focus on compounds that exclusively block nociceptor function, while leaving the activity of other cell types, such as motor neurons or heart cells, unaffected. This selective targeting is a key preclinical marker of safety and specificity. These compounds then will be comprehensively analyzed for their molecular and biological characteristics, including effects on gene expression, protein production and cell physiology.

These data will be combined with insights drawn from INDRA (Integrated Network and Dynamical Reasoning Assembler), a powerful artificial intelligence system developed at the LSP, which automatically parses the scientific literature and public databases to construct models of gene and protein networks that can then be tested in the lab.

Together, these analyses aim to articulate the precise molecular mechanisms by which compounds inhibit nociceptor function and reveal the specific molecular targets involved in order to inform further drug development.

Once fully characterized, promising compounds will be refined or redesigned through computational and experimental chemistry techniques to maximize their potential efficacy.

The compounds will then be tested for safety and efficacy for pain management in preclinical models and through new machine vision and learning tools developed by the consortium.

By integrating these complementary approaches, the STOP PAIN consortium intends to generate thoroughly evaluated drug candidates for submission to the U.S. Food and Drug Administration for Investigational New Drug designation.

In addition, the team believes that the shift from a target-based approach to a cell-based screening approach backed up by sophisticated computational modeling could help transform the process of drug discovery and validation by offering an alternative model to address other critical unmet therapeutic needs.

Drug development is notoriously slow and arduous, but the researchers say they are optimistic that the depth and breadth of their collective expertise--drawn from multiple disciplines and institutions--makes it possible to develop drug candidates suitable for human clinical trials within the five-year time frame of the project. As one measure of progress, new compounds are already being synthesized and tested by the team.

This project is closely aligned with the recently launched Therapeutics Initiative at HMS, which aims to expedite the translation of basic science discoveries into new treatments for patients.

To this end, the consortium will pursue development of the most promising drug candidates through new ventures or collaborations with existing pharmaceutical or biotech companies. This includes working with life sciences incubators such as the Pagliuca Harvard Life Lab or the recently announced Blavatnik Harvard Life Lab Longwood, which both support early-stage, high-potential biotech and life sciences projects from the Harvard community.

"The development of safer medications to replace prescription opioids for pain management remains one of the most pressing unmet needs in medicine," said George Q. Daley, Dean of HMS. "This ambitious multi-institutional consortium offers promise for improving the health and well-being of countless patients and families."

Read the original here:
Consortium launches ambitious project to transform the treatment of pain - News-Medical.net

Researchers use imaging to reveal early stages of colon cancer – Drug Target Review

A study has demonstrated how mutations in early colon cancer prevail and grow into malignancies, using fluorescent imaging.

Researchers have revealed how stem cell mutations arise and spread throughout a widening field of the colon until they eventually become a malignancy. According to the team, their technique could lead to therapeutic developments and earlier treatment of the disease.

High magnification image of fluorescent intestinal stem cells. Each fluorescent colour is used as a barcode to visualise human colon cancer-causing mutations in mice (credit: Duke Health).

The study was conducted at the Duke Cancer Institute at Duke University, US.

Using an innovative modelling system in mice, the researchers visually tagged colon cancer mutations by causing stem cells to grow. This allowed them to identify the prevailing mutations, which could be visualised in the animals.

The team tagged several common colon cancer mutations in the stem cells of a single tumour to create a fluorescent barcode. When transferred to a mouse, the colours of the stem cells could be tracked, revealing the cellular and molecular dynamics of the pre-cancerous events.

The researchers suggest that their technique can be used to discover field cancerisation, which is suggested to be the defining event that initiates the process of cancer growth.

This study provides new insight into the previously invisible process in which mutant pre-cancerous stem cells spread throughout the colon and seed cancer, said Dr Joshua Snyder, Assistant Professor in the Departments of Surgery and Cell Biology at Duke and corresponding and co-senior author.

Our technique sets a firm foundation for testing new therapies that interrupt this early, pre-malignant process. We hope to one day target and eliminate these stealth precancerous cells to prevent cancer, Snyder continued.

The findings were published in Nature Communications.

See more here:
Researchers use imaging to reveal early stages of colon cancer - Drug Target Review

Innate Pharma Certified as a Great Place to Work – GlobeNewswire

Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) today announced its certification as a great work place by the independent institute, Great Place to Work, a global authority on workplace culture, employee experience and leadership behaviors. This recognition was based extensively on ratings provided by Innate Pharma's employees in an anonymous survey that assessed perspectives on leadership, organizational culture and trust.

We are very proud to have obtained the Great Place to Work certification, which acknowledges a high-performing and collaborative culture that attracts, engages and develops its employees," said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. In the highly competitive biotech industry, our success depends on our ability to foster a positive company culture. Its rewarding to see the time, resources and energy weve committed around collaborating, listening and communicating to employees, reflected in our high levels of employee engagement and recognized by this external validation.

Eighty-six percent of employees participated in the Great Place to Work survey process. Managerial practices, collaborative spirit, working conditions and commitment to the company were identified as main strengths of the company.

"Congratulations to Innate Pharma for being one of the Great Place to Work 2019 certified companies. This innovative company, with a strong social mission, has succeeded in getting employees to support its corporate culture and mission. As such, 90 percent of employees say they are proud to tell others that they are working for Innate Pharma. Thus, the Great Place to Work project, led by the company's highest level of management, contributes to making it a great place to work, said Patrick Dumoulin, President of Great Place to Work France.

About Great Place to Work

Great Place to Work is the global authority on workplace culture.Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified companies and the Best Workplaces in the US and more than 60 countries, including the 100 Best Companies to Work For and World's Best list published annually in Fortune. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work For All. To learn more, visit greatplacetowork.com.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharmas commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at http://www.innate-pharma.com

Information about Innate Pharma shares:

Disclaimer:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements.Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts and the Companys continued ability to raise capital to fund its development.For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (AMF), which is available on the AMF website http://www.amf-france.org or on Innate Pharmas website, and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC), including the Companys final prospectus dated October 16, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Read this article:
Innate Pharma Certified as a Great Place to Work - GlobeNewswire

Fat grafting improves range of motion in limbs damaged by radiation therapy – PR Web

Researchers: Derrick C. Wan, MD, FACS and Arash Momeni, MD, FACS

DURHAM, N.C. (PRWEB) December 03, 2019

A new study released today in STEM CELLS outlines how fat grafting which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

The tumor-destroying capabilities of radiation therapy can be a life saver for a person suffering from cancer. But its a therapy that has several unwanted side effects, too, including causing substantial damage not just to cancerous cells, but any healthy tissue in its path. Over time, fibrosis builds up in the treated area which, in the case of an arm, shoulder, or leg, for example, can lead to painful contractures that significantly limit extensibility and negatively impact the persons quality of life.

The Stanford team irradiated the right hind legs of subject mice, which resulted in chronic fibrosis and limb contracture. Four weeks later, the irradiated limbs of one group of the mice were injected with fat enriched with stromal vascular cells (SVCs). These potent cells already naturally exist in fat, but supplementation of fat with additional SVCs enhances its regenerative capabilities. A second group was injected with fat only, a third group with saline and a fourth group received no injections, for comparison. The animals ability to extend their limb was then measured at baseline and every two weeks for a 12-week period. At the end of the 12 weeks, the hind limb skin underwent histological analysis and biomechanical strength testing.

Each animal showed significant reduction in its limb extension ability due to the radiation, but this was progressively rescued by fat grafting, reported corresponding author Derrick C. Wan, M.D., FACS. Fat grafting also reduced skin stiffness and reversed the radiation-induced histological changes in the skin.

The greatest benefits were found in mice injected with fat enriched with SVCs, Dr. Wan added. SVCs are easily obtained through liposuction and can be coaxed into different tissue types, where they can support neovascularization, replace cells and repair injured issue.

Our study showed the ability of fat to improve mobility as well as vascularity and appearance, he continued. We think this holds enormous clinical potential especially given that adipose tissue is abundant and can be easily collected from the patients themselves and underscores an attractive approach to address challenging soft tissue fibrosis in patients following radiation therapy.

Furthermore, said co-author and world-renowned breast reconstructive expert Arash Momeni, M.D., FACS, Our observations are potentially translatable to a variety of challenging clinical scenarios. Being able to reverse radiation-induced effects holds promise to substantially improve clinical outcomes in implant-based as well as autologous breast reconstruction. The study findings are indeed encouraging as they could offer patients novel treatment modalities for debility clinical conditions.

Excessive scarring is a challenging problem that is associated with a variety of clinical conditions, such as burn injuries, tendon lacerations, etc. The potential to improve outcomes based on treatment modalities derived from our research is indeed exciting, Dr. Momeni added.

"Skin and soft tissue scarring and fibrosis are well-established problems after radiation. The current study, showing that human fat grafting can normalize the collagen networks and improve tissue elasticity in immune deficient mice, provides molecular evidence for how fat grafting functions, said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. The studies indicate that, with the appropriate regulatory approvals, autologous fat grafting could potentially also help human patients recover from radiation-induced tissue fibrosis.

The full article, Fat grafting rescues radiation-induced joint contracture, can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.3115.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Share article on social media or email:

Read this article:
Fat grafting improves range of motion in limbs damaged by radiation therapy - PR Web

Raiders Of The Lost Crops: Scientists Race Against Time To Save Genetic Diversity – NPR

Members of the Crop Wild Relatives project from the Crop Trust joined their research partners in Nepal on an expedition to collect wild relatives of rice, okra and eggplant in October 2017. Hannes Dempewolf of the Crop Trust says the elephants kept the researchers high enough off the ground that they didn't have to worry about any snakes that might be lurking. L.M. Salazar/Crop Trust hide caption

Members of the Crop Wild Relatives project from the Crop Trust joined their research partners in Nepal on an expedition to collect wild relatives of rice, okra and eggplant in October 2017. Hannes Dempewolf of the Crop Trust says the elephants kept the researchers high enough off the ground that they didn't have to worry about any snakes that might be lurking.

Call it a tale of science and derring-do. An international team of researchers has spent six years fanning across the globe, gathering thousands of samples of wild relatives of crops. Their goal: to preserve genetic diversity that could help key crops survive in the face of climate change. At times, the work put these scientists in some pretty extreme situations.

Just ask Hannes Dempewolf. Two years ago, the plant geneticist found himself in a rainforest in Nepal, at the foot of the Himalayas. He was riding on the back of an elephant to avoid snakes on the ground and to scare away any tigers that might be lurking about. Then all of a sudden came an attack from above.

"There were leeches dropping on us from all directions," Dempewolf recalls "bloodsucking leeches."

Now, this is far from where he thought he'd be when he got his Ph.D. But as a senior scientist and head of global initiatives at the Crop Trust, Dempewolf has been overseeing an ambitious international collaboration. More than 100 scientists in 25 countries have been venturing out to collect wild relatives of domesticated crops like lentils, potatoes, chickpeas and rice that people rely on around the world. The Crop Trust has just released a report detailing the results of this massive effort, which secured more than 4,600 seed samples of 371 wild relatives of key domesticated crops that the world relies on.

The "collecting teams are heading out into wild places and hard-to-reach corners within their countries to try to find and track down some of these wild species that have either never been collected before or are very underrepresented in seed banks," Dempewolf explains. So he says it's not surprising that many of the stories coming out of the project have an Indiana Jones-like sense of adventure to them.

Take, for example, an effort to collect Oryza glumaepatula, a wild rice species found in Latin America. Griselda Arrieta Espinoza, a crop genetics and biotechnology researcher at the University of Costa Rica, was part of a collecting team that set out to northern Costa Rica to collect a particular population of this wild rice that grows in a river. "Collecting it was quite the adventure," she tells me in Spanish because the river is also home to crocodiles.

While the effort was dangerous, Arrieta says it was also worth it, because Oryza glumaepatula is known to be resistant to a fungus that attacks domesticated rice grown around the world. And she notes that researchers in Brazil have already managed to cross Oryza glumaepatula with domesticated rice to improve crop yields.

Jamal Mabrouki, a technician with the International Center for Agricultural Research in the Dry Areas, works on a grasspea breeding project at ICARDA's facilities at Marchouch station, Morocco. Michael Major/Crop Trust hide caption

Jamal Mabrouki, a technician with the International Center for Agricultural Research in the Dry Areas, works on a grasspea breeding project at ICARDA's facilities at Marchouch station, Morocco.

The overall goal of the Crop Trust project is to make sure that this kind of valuable genetic diversity is preserved in seed banks before wild crop relatives disappear as urban development encroaches on once wild habitats. Dempewolf says that this is already happening.

"Some of the populations that the [research teams] were hoping to collect, when they reached the areas where they had seen populations before, they had disappeared," Dempewolf says.

Steven Tanksley, a professor emeritus of plant breeding at Cornell University, who was not involved in the Crop Trust project, praised the effort. He notes that the domesticated crops we eat today were selected from wild plants over thousands of years. He says this "natural reservoir of diversity ... has allowed plant breeding to attempt to keep pace with the demands of the growing human population."

That diversity took shape over millions of years, molded by natural selection, so "when you lose it, you really can't repeat that process," says Tanksley, who is also chief technology officer for Nature Source Improved Plants, which focuses on the genetic improvement of plants.

In the past, he notes, breeders have used wild crop relatives to improve disease resistance in many domesticated crops, including tomatoes, potatoes, rice and wheat.

A growing global population and changing environmental conditions because of climate change present urgent new challenges for crop breeders, Tanksley says.

"If we're going to have a sustainable world with a sustainable environment, we have to produce a lot more food per hectare than we ever have in the past," he says, adding, "I think people don't really grasp that the urgency of it."

And without the genetic diversity of wild crop relatives, he says, the world will have little chance of keeping up with growing demand for food.

Visit link:
Raiders Of The Lost Crops: Scientists Race Against Time To Save Genetic Diversity - NPR

The thrill of genetic genealogical discoveries should be tempered by ethical concerns – The Jewish News of Northern California

In these times of alarming disregard for scientific data (were talking to you, climate change deniers), lets hear it for science, specifically the astonishing gains made in the field of genetics and genetic testing.

Our three-part Past Lives series highlights the extraordinary resources now readily available to anyone curious about their family ancestry. Easy access to family records on the internet and the mapping of the human genome allows us to peer into our genetic past to learn more about who we are. And we can do both kinds of research from the comfort of our own homes.

For Jews, this has been a blessing for the most part. Unlike those Americans descended from Western European populations who can turn to comprehensive written archives, such as baptismal and marriage records, most Ashkenazi Jews like African Americans and Hispanic Americans lack the paper trail to trace their ancestry back further than a few generations.

Now, with the evolution of genetic testing, we can pinpoint to a remarkable degree of precision the composition of our ethnicity and where we came from. And all it takes is a simple cheek swab.

For some, discovering Jewish roots opens the door to new connections and layers of spiritual meaning.

As our stories show, this technology is about more than percentages and places on the map. For some, discovering the very existence of Jewish roots is a personal marvel, opening the door to new connections and layers of spiritual meaning.

However, as with any technology, ethical concerns run rampant.

Are we now as a global kehillah to rely on DNA test results as a proving ground for belonging to the Jewish people? What about those who convert to Judaism and might hail from different backgrounds? When their DNA pie chart comes back with zero percent Jewishness, does that mean they are any less Jewish?

Though matrilineal descent long ago enshrined a genetic aspect to Judaism, have we not seen enough of eugenics, racism, white nationalism and hate-fueled violence to check a rush to embrace anything that smacks of genetic purity?

These concerns have come to the forefront in Israel, where for the past two years the Chief Rabbinate has been using genetic testing to confirm the Jewishness of immigrants from the former Soviet Union seeking marriage licenses, in cases where the applicants dont have sufficient documentation of their status. Dozens of young couples, and their close relatives, have been humiliated in this way, and the practice is now being challenged before Israels High Court, brought there by the largely immigrant Yisrael Beiteinu party.

Scientific discoveries often involve thorny ethical questions. They must be faced openly.

View post:
The thrill of genetic genealogical discoveries should be tempered by ethical concerns - The Jewish News of Northern California

China Uses DNA to Map Faces, With Help From the West – The New York Times

TUMXUK, China In a dusty city in the Xinjiang region on Chinas western frontier, the authorities are testing the rules of science.

With a million or more ethnic Uighurs and others from predominantly Muslim minority groups swept up in detentions across Xinjiang, officials in Tumxuk have gathered blood samples from hundreds of Uighurs part of a mass DNA collection effort dogged by questions about consent and how the data will be used.

In Tumxuk, at least, there is a partial answer: Chinese scientists are trying to find a way to use a DNA sample to create an image of a persons face.

The technology, which is also being developed in the United States and elsewhere, is in the early stages of development and can produce rough pictures good enough only to narrow a manhunt or perhaps eliminate suspects. But given the crackdown in Xinjiang, experts on ethics in science worry that China is building a tool that could be used to justify and intensify racial profiling and other state discrimination against Uighurs.

In the long term, experts say, it may even be possible for the Communist government to feed images produced from a DNA sample into the mass surveillance and facial recognition systems that it is building, tightening its grip on society by improving its ability to track dissidents and protesters as well as criminals.

Some of this research is taking place in labs run by Chinas Ministry of Public Security, and at least two Chinese scientists working with the ministry on the technology have received funding from respected institutions in Europe. International scientific journals have published their findings without examining the origin of the DNA used in the studies or vetting the ethical questions raised by collecting such samples in Xinjiang.

In papers, the Chinese scientists said they followed norms set by international associations of scientists, which would require that the men in Tumxuk (pronounced TUM-shook) gave their blood willingly. But in Xinjiang, many people have no choice. The government collects samples under the veneer of a mandatory health checkup program, according to Uighurs who have fled the country. Those placed in internment camps two of which are in Tumxuk also have little choice.

The police prevented reporters from The New York Times from interviewing Tumxuk residents, making verifying consent impossible. Many residents had vanished in any case. On the road to one of the internment camps, an entire neighborhood had been bulldozed into rubble.

Growing numbers of scientists and human rights activists say the Chinese government is exploiting the openness of the international scientific community to harness research into the human genome for questionable purposes.

Already, China is exploring using facial recognition technology to sort people by ethnicity. It is also researching how to use DNA to tell if a person is a Uighur. Research on the genetics behind the faces of Tumxuks men could help bridge the two.

The Chinese government is building essentially technologies used for hunting people, said Mark Munsterhjelm, an assistant professor at the University of Windsor in Ontario who tracks Chinese interest in the technology.

In the world of science, Dr. Munsterhjelm said, theres a kind of culture of complacency that has now given way to complicity.

Sketching someones face based solely on a DNA sample sounds like science fiction. It isnt.

The process is called DNA phenotyping. Scientists use it to analyze genes for traits like skin color, eye color and ancestry. A handful of companies and scientists are trying to perfect the science to create facial images sharp and accurate enough to identify criminals and victims.

The Maryland police used it last year to identify a murder victim. In 2015, the police in North Carolina arrested a man on two counts of murder after crime-scene DNA indicated the killer had fair skin, brown or hazel eyes, dark hair, and little evidence of freckling. The man pleaded guilty.

Despite such examples, experts widely question phenotypings effectiveness. Currently, it often produces facial images that are too smooth or indistinct to look like the face being replicated. DNA cannot indicate other factors that determine how people look, such as age or weight. DNA can reveal gender and ancestry, but the technology can be hit or miss when it comes to generating an image as specific as a face.

Phenotyping also raises ethical issues, said Pilar Ossorio, a professor of law and bioethics at the University of Wisconsin-Madison. The police could use it to round up large numbers of people who resemble a suspect, or use it to target ethnic groups. And the technology raises fundamental issues of consent from those who never wanted to be in a database to begin with.

What the Chinese government is doing should be a warning to everybody who kind of goes along happily thinking, How could anyone be worried about these technologies? Dr. Ossorio said.

With the ability to reconstruct faces, the Chinese police would have yet another genetic tool for social control. The authorities have already gathered millions of DNA samples in Xinjiang. They have also collected data from the hundreds of thousands of Uighurs and members of other minority groups locked up in detention camps in Xinjiang as part of a campaign to stop terrorism. Chinese officials have depicted the camps as benign facilities that offer vocational training, though documents describe prisonlike conditions, while testimonies from many who have been inside cite overcrowding and torture.

Even beyond the Uighurs, China has the worlds largest DNA database, with more than 80 million profiles as of July, according to Chinese news reports.

If I were to find DNA at a crime scene, the first thing I would do is to find a match in the 80 million data set, said Peter Claes, an imaging specialist at the Catholic University of Leuven in Belgium, who has studied DNA-based facial reconstruction for a decade. But what do you do if you dont find a match?

Though the technology is far from accurate, he said, DNA phenotyping can bring a solution.

To unlock the genetic mysteries behind the human face, the police in China turned to Chinese scientists with connections to leading institutions in Europe.

One of them was Tang Kun, a specialist in human genetic diversity at the Shanghai-based Partner Institute for Computational Biology, which was founded in part by the Max Planck Society, a top research group in Germany.

The German organization also provided $22,000 a year in funding to Dr. Tang because he conducted research at an institute affiliated with it, said Christina Beck, a spokeswoman for the Max Planck Society. Dr. Tang said the grant had run out before he began working with the police, according to Dr. Beck.

Another expert involved in the research was Liu Fan, a professor at the Beijing Institute of Genomics who is also an adjunct assistant professor at Erasmus University Medical Center in the Netherlands.

Both were named as authors of a 2018 study on Uighur faces in the journal Hereditas (Beijing), published by the government-backed Chinese Academy of Sciences. They were also listed as authors of a study examining DNA samples taken last year from 612 Uighurs in Tumxuk that appeared in April in Human Genetics, a journal published by Springer Nature, which also publishes the influential journal Nature.

Both papers named numerous other authors, including Li Caixia, chief forensic scientist at the Ministry of Public Security.

In an interview, Dr. Tang said he did not know why he was named as an author of the April paper, though he said it might have been because his graduate students worked on it. He said he had ended his affiliation with the Chinese police in 2017 because he felt their biological samples and research were subpar.

To be frank, you overestimate how genius the Chinese police is, said Dr. Tang, who had recently shut down a business focused on DNA testing and ancestry.

Like other geneticists, Dr. Tang has long been fascinated by Uighurs because their mix of European and East Asian features can help scientists identify genetic variants associated with physical traits. In his earlier studies, he said, he collected blood samples himself from willing subjects.

Dr. Tang said the police approached him in 2016, offering access to DNA samples and funding. At the time, he was a professor at the Partner Institute for Computational Biology, which is run by the Chinese Academy of Sciences but was founded in 2005 in part with funding from the Max Planck Society and still receives some grants and recommendations for researchers from the German group.

Dr. Beck, the Max Planck spokeswoman, said Dr. Tang had told the organization that he began working with the police in 2017, after it had stopped funding his research a year earlier.

But an employment ad on a government website suggests the relationship began earlier. The Ministry of Public Security placed the ad in 2016 seeking a researcher to help explore the DNA of physical appearance traits. It said the person would report to Dr. Tang and to Dr. Li, the ministrys chief forensic scientist.

Dr. Tang did not respond to additional requests for comment. The Max Planck Society said Dr. Tang had not reported his work with the police as required while holding a position at the Partner Institute, which he did not leave until last year.

The Max Planck Society takes this issue very seriously said will ask its ethics council to review the matter, Dr. Beck said.

It is not clear when Dr. Liu, the assistant professor at Erasmus University Medical Center, began working with the Chinese police. Dr. Liu says in his online rsum that he is a visiting professor at the Ministry of Public Security at a lab for on-site traceability technology.

In 2015, while holding a position with Erasmus, he also took a post at the Beijing Institute of Genomics. Two months later, the Beijing institute signed an agreement with the Chinese police to establish an innovation center to study cutting-edge technologies urgently needed by the public security forces, according to the institutes website.

Dr. Liu did not respond to requests for comment.

Erasmus said that Dr. Liu remained employed by the university as a part-time researcher and that his position in China was totally independent of the one in the Netherlands. It added that Dr. Liu had not received any funding from the university for the research papers, though he listed his affiliation with Erasmus on the studies. Erasmus made inquiries about his research and determined there was no need for further action, according to a spokeswoman.

Erasmus added that it could not be held responsible for any research that has not taken place under the auspices of Erasmus by Dr. Liu, even though it continued to employ him.

Still, Dr. Lius work suggests that sources of funding could be mingled.

In September, he was one of seven authors of a paper on height in Europeans published in the journal Forensic Science International. The paper said it was backed by a grant from the European Union and by a grant from Chinas Ministry of Public Security.

Dr. Tang said he was unaware of the origins of the DNA samples examined in the two papers, the 2018 paper in Hereditas (Beijing) and the Human Genetics paper published in April. The publishers of the papers said they were unaware, too.

Hereditas (Beijing) did not respond to a request for comment. Human Genetics said it had to trust scientists who said they had received informed consent from donors. Local ethics committees are generally responsible for verifying that the rules were followed, it said.

Springer Nature said on Monday that it had strengthened its guidelines on papers involving vulnerable groups of people and that it would add notes of concern to previously published papers.

In the papers, the authors said their methods had been approved by the ethics committee of the Institute of Forensic Science of China. That organization is part of the Ministry of Public Security, Chinas police.

With 161,000 residents, most of them Uighurs, the agricultural settlement of Tumxuk is governed by the powerful Xinjiang Production and Construction Corps, a quasi-military organization formed by decommissioned soldiers sent to Xinjiang in the 1950s to develop the region.

The state news media described Tumxuk, which is dotted with police checkpoints, as one of the gateways and major battlefields for Xinjiangs security work.

In January 2018, the town got a high-tech addition: a forensic DNA lab run by the Institute of Forensic Science of China, the same police research group responsible for the work on DNA phenotyping.

Procurement documents showed the lab relied on software systems made by Thermo Fisher Scientific, a Massachusetts company, to work with genetic sequencers that analyze DNA fragments. Thermo Fisher announced in February that it would suspend sales to the region, saying in a statement that it had decided to do so after undertaking fact-specific assessments.

For the Human Genetics study, samples were processed by a higher-end sequencer made by an American firm, Illumina, according to the authors. It is not clear who owned the sequencer. Illumina did not respond to requests for comment.

The police sought to prevent two Times reporters from conducting interviews in Tumxuk, stopping them upon arrival at the airport for interrogation. Government minders then tailed the reporters and later forced them to delete all photos, audio and video recordings taken on their phones in Tumxuk.

Uighurs and human rights groups have said the authorities collected DNA samples, images of irises and other personal data during mandatory health checks.

In an interview, Zhou Fang, the head of the health commission in Tumxuk, said residents voluntarily accepted free health checks under a public health program known as Physicals for All and denied that DNA samples were collected.

Ive never heard of such a thing, he said.

The questions angered Zhao Hai, the deputy head of Tumxuks foreign affairs office. He called a Times reporter shameless for asking a question linking the health checks with the collection of DNA samples.

Do you think America has the ability to do these free health checks? he asked. Only the Communist Party can do that!

See the article here:
China Uses DNA to Map Faces, With Help From the West - The New York Times

Kim Kardashian West’s battle with psoriatic arthritis: Will understanding the genetics of the autoimmune disorder point to a cure? – Genetic Literacy…

In September, the world of entertainment news buzzed with word that Kim Kardashian West tested positive for lupus and rheumatoid arthritis. The star underwent further tests, however, resulting in a diagnosis of psoriatic arthritis instead. While all three autoimmune disorders share some signs and symptoms, psoriatic arthritis is generally considered to have a better prognosis than lupus. That said, the conditions can co-exist and lupus has gotten a reputation for being difficult to diagnose, especially in the absence of the butterfly-shaped rash on ones cheeks and nose.

Im so relieved. The pain is going to come and go sometimes, but I can manage it and this is not going to stop me, Kardashian said in an article in response to receiving her psoriatic arthritis diagnosis. Her relief at not having lupus is understandable, given that lupus can affect a greater number of organs and systems in the body and is considered to be life-threatening.

Lupus, rheumatoid arthritis and psoriatic arthritis are examples of some conditions that are often considered when an individual is undergoing diagnosis for certain autoimmune diseases, because they share several symptoms and can trigger positive results in the same diagnostic tests. Kim Kardashian received the initial news that she had lupus or rheumatoid arthritis likely due to positive antinuclear antibody (ANA) test results.

An ANA is a blood test ordered when a doctor, usually a rheumatologist, suspects that a patient has a particular kind of autoimmune disorder. This test checks for the existence of autoantibodies, which are produced when a persons body is, in effect, attacking itself and several areas of the body are affected. A positive ANA test usually indicates that the doctors suspicions are confirmed, and then other factors (like medical and family history) need to be considered and more tests done to arrive at a diagnosis.

Psoriatic arthritis is usually diagnosed between the ages of 20 and 50, and occurs in women and men equally. While there is no cure, appropriate and early treatment can help prevent major damage to affected parts of the body.

Psoriatic arthritis appears in a minority of individuals who have already been diagnosed with psoriasis, an autoimmune skin condition with which Kim Kardashian and her mother, Kris Jenner, had already been diagnosed. Psoriatic arthritis affects around 520,000 individuals in the United States alone.

The autoimmune condition is believed to be caused by a combination of genetic factors and environmental triggers. So while some people inherit psoriatic arthritis-related genes, only a subset of those individuals will go on to develop the condition. In these cases, the disease could be triggered by other illnesses or infections, various forms of extreme stress, poor diet, smoking, and so on.

Around 40 percent of psoriatic arthritis patients have one or more close family members with psoriasis or psoriatic arthritis diagnosis, which strongly indicates that the disease is hereditary. Interestingly, recent research has suggested that psoriasis patients who go on to develop psoriatic arthritis have a different genetic profile than those who do not. And the most well-studied of the psoriatic arthritis genes belong to a family of genes called the human leukocyte antigen (HLA) complex, which help the body tell the difference between its own proteins and viral or bacterial proteins.

According to Genetics Home Reference by the U.S. National Library of Medicine, Variations of several HLA genes seem to affect the risk of developing psoriatic arthritis, as well as the type, severity, and progression of the condition.

Ive been feeling so tired, so nauseous, and my hands are really getting swollen. I feel like I literally am falling apart. My hands are numb, Kardashian said on a recent episode of Keeping Up with the Kardashians.

These kinds of descriptions are common in all three conditions lupus, rheumatoid arthritis, and psoriatic arthritis though each patient presents with a different array of symptoms, and all with varying degrees of severity. The main symptoms of psoriatic arthritis are pain, stiffness, and swelling in affected joints, along with chronic fatigue. Joints near the end of the fingertips and tips of the toes are often affected, as are bones in the spine.

The symptoms of psoriatic arthritis tend to worsen over time, though some patients experience periods of remission when symptoms temporarily improve. Compared to rheumatoid arthritis, psoriatic arthritis is more likely to cause swelling in the smallest joints of the fingers and toes, foot pain (in the heel and/or sole of the foot), and lower back pain caused by inflammation in vertebral joints. Patients with psoriatic arthritis are also more likely to experience symptoms on one side of the body or in different appendages on each side (in other words, it tends to be an asymmetric disease), whereas patients with rheumatoid arthritis are more likely to experience symptoms that affect both sides of the body equally (symmetric disease).

Most if not all patients with psoriatic arthritis also have psoriasis, an autoimmune condition that causes red, scaly patches of skin that can be itchy, painful and embarrassing. Psoriasis usually precedes the onset of psoriatic arthritis by several years. People with psoriatic arthritis commonly experience fingernail changes, too, such as the formation of a pitted or ridged nail surface, or the nails become separated from the nail beds.

There are several treatment options for psoriatic arthritis, which include nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain, immunosuppressants to suppress the immune system, disease-modifying antirheumatic drugs (DMARDs) to slow the progression of the disease, and newer medications that minimize the activity of certain enzymes involved in the inflammatory process. Treatment plans may also involve steroid injections administered directly into affected joints, or joint replacement surgery in cases where the disease has significantly progressed.

Kristen Hovet covers genetics, medical innovations and the intersection of sociology and culture. The North Dakota native is based in Vancouver, Canada, where she is working on a masters degree in health communication at Washington State University. Follow her on her website or Twitter @kristenhovet

More:
Kim Kardashian West's battle with psoriatic arthritis: Will understanding the genetics of the autoimmune disorder point to a cure? - Genetic Literacy...

Why Are These Foxes Tame? Maybe They Werent So Wild to Begin With – The New York Times

In the 1950s, Dmitri K. Belyaev began one of the most famous experiments in animal domestication. Dr. Belyaev, a geneticist at the Institute of Cytology and Genetics in Novosibirsk, Russia, selectively bred foxes that he had acquired from a fur farm, concentrating only on reducing their fear of humans.

Within 10 generations, he wrote in 1979, Like dogs, these foxes seek contact with familiar persons, tend to get close to them, and lick their hands and faces.

In a new paper in the journal Trends in Ecology and Evolution, several scientists have challenged a common interpretation of Dr. Belyaevs results, and have questioned whether scientists who study domestication have any common understanding of what the word means.

The authors dont dispute the essence of Dr. Belyaevs work: the selection for tameness, which is regarded as profoundly important in exploring the genetics and evolution of behavior.

But that wasnt all that Dr. Belyaev discovered. His foxes also showed physical changes, like piebald coats and floppy ears characteristics shared by dogs, cows and other domesticated animals.

Dr. Belyaev and the researchers who followed up his work suggested, as had Charles Darwin before them, that there might be a collection of physical traits that go along with tameness called domestication syndrome.

The authors of the new paper argue that this idea is undermined by an intriguing sub-chapter in the long history of the fur trade in Canada. The reaction to that criticism from other scientists has been mixed, reflecting contentious but cordial disagreements about what domestication is and how it happens.

The average pet lover may know the story of the foxes from a book by Lee Alan Dugatkin and Lyudmila Trut, who collaborated with Dr. Belyaev, called How to Tame a Fox (and Build a Dog).

Far fewer people probably know about the development of fox farming on Prince Edward Island, Canadas smallest province. This history is buried in plain sight, you might say, since you can learn about it easily if you visit International Fox Museum and Hall of Fame on the island.

The museum is not a common destination for evolutionary biologists who specialize in domestication. But one of them did visit back in 2015, and he was taken aback.

The late Raymond Coppinger, a biologist at Hampshire College in Massachusetts who was a major contributor to the study of dog evolution, toured the museum and returned full of questions.

He saw these pictures of spotted foxes, and they looked just like the Belyaev foxes, recalled Kathryn Lord, an animal behaviorist at the Broad Institute in Cambridge, Mass., and the first author of the new paper. Dr. Coppinger was her mentor at Hampshire College.

There have been academic reports as well, suggesting that the Russian foxes hailed from Prince Edward Island, Dr. Lord said: Different pieces of the story were all over, but nobody had put it together.

As it turned out, genetic tests showed that Dr. Belyaevs foxes did have roots in eastern Canada, which almost certainly meant Prince Edward Island. So the question bothering Dr. Coppinger and Dr. Lord was this: How much domestication had gone on before the famous fox experiment began?

She got the attention of Elinor Karlsson, a geneticist at the Broad Institute in whose lab Dr. Lord worked. And she drew in Greger Larson, a specialist in ancient canine DNA at the University of Oxford in England, who is deeply involved in questions of dog evolution and domestication. They began to refine the work Dr. Lord and Dr. Coppinger had already done.

Dr. Belyaev had plainly stated that his foxes were from farmed stock. So some domestication must have occurred before his experiment, said Anna Kukekova, a geneticist at the University of Illinois who researches the genetics of Russian foxes and has collaborated with Dr. Trut.

Dr. Belyaev recognized that fur farmers would have chosen animals that were at least somewhat tolerant of people, Dr. Kukekova said. But Dr. Belyaev also described his foxes as mostly uncomfortable with people, virtually wild animals. Now, Dr. Lord and her colleagues suggest otherwise.

Fox-farming pioneers on Prince Edward Island began by breeding wild-caught black foxes, also called silver foxes, a color variant of the red fox (Vulpes vulpes) common all over the world.

They were bred mainly for the look of the pelts. In 1910, one company sold 25 skins for $34,649.50, according to Silver Fox Odyssey: History of the Canadian Silver Fox Industry.

Then breeding stock became more profitable. Old proven breeders of good quality were valued during the last months of 1912 at from $18,000 to $25,000 a pair, according to a 1913 report by the Canadian government quoted in Silver Fox Odyssey. Eventually the industry declined, and there are only traces of it remaining.

The museum on Prince Edward Island has old photographs that show foxes looking very comfortable with human beings. And as Dr. Lord took a deep dive into fox-farming history, she found other sources suggesting the animals were already somewhat domesticated, including The Black Fox Magazine, a publication for people who hoped to make their fortune raising foxes for their pelts.

The magazine offers a glimpse into a bygone world. For example, an article by F. E. Muzzy in the January 1921 issue described the 1921 International Fox Show in Montreal. Mr. Muzzy wrote that one of the islands fox industry bigwigs, Leo Frank, brought a pair of tame foxes to town, and not only walked them on leashes but took them to a dance where the girls did the fox trot with these foxes around their necks.

Hearsay, of course, but a good story, given the other evidence.

Dr. Belyaevs claims in his landmark article were twofold. One, he had shown how quickly one could select for tameness and tolerance of human beings. The second was that breeding, or selecting for lack of fear in the presence of humans, also had brought about other changes, like floppy ears, spotted coats and differences in tail carriage.

He didnt use the term, but that suite of physical traits came to be known as domestication syndrome. And it was thought to cross species, showing up in cows and goats, for example, as well as foxes.

The idea of domestication syndrome, said Dr. Larson, has been appealing but not thoroughly examined. He, Dr. Lord and their colleagues looked at 10 papers that defined domestication syndrome and found that there wasnt one trait that was included in all the definitions. What the hell are we even talking about here? he asked.

The authors argue that the foxes already showed some of the physical traits that Dr. Belyaev described by the time he got them. His breeding may, however have affected how frequently the traits appeared.

The researchers also note that different species show different combinations of the traits that were proposed to be in the syndrome.

The paper provides the final nail in the coffin to the idea of a universal set of traits characterizing all domesticated animals, said Marcelo R. Snchez-Villagra, a professor of paleobiology at the University of Zurich who studies domestication and was not involved in the study.

But that was not surprising, he added, given other research showing varying processes of domestication. He appreciated the critical look at the fox experiment, because I also think its value has been overestimated.

Dr. Kukekova said she found that critique oversimplified, although she sympathized: I completely understand their frustration with domestication syndrome.

But many aspects of the fox domestication experiment were not presented correctly, she added.

Dr. Belyaev created a pattern of behavior totally different from that of the farmed foxes he began with, Dr. Kukekova said. The old photographs of the friendly foxes were not scientific evidence, she added, and there was no evidence that the foxes actively sought out human interaction, as Dr. Belyaevs did.

She cautioned, however, that there is an enormous difference between a domesticated animal and a pet. The foxes are domesticated, but they are not pets, she said.

Adam Wilkins, a biologist at Humboldt University in Berlin, found the new paper deeply flawed. In a personal letter to the authors, he argued that mammals do share a suite of physical characteristics that go along with tameness.

Dr. Wilkins has argued that mutations in cells in a part of the embryo called the neural crest are linked to behavioral and physical changes.

The fact that different kinds of domesticated animals have somewhat different sets of the affected traits is perfectly consistent with the idea of a syndrome, he wrote in an email.

Asked if there was a working definition of domestication, Dr. Sanchez-Villagra replied, There are as many as there are authors who have provided a definition.

Despite their differences, the spirit of collaboration and scientific discourse among researchers in the quite small field of canine evolution might best be captured by Dr. Wilkins at the end of his letter.

He tempered his criticisms with a friendly note, concluding, We clearly share a strong interest in the subject and I suspect a love of dogs. Here, I attach a picture of my personal favorite domesticated animal, my dog Wolfie.

See the article here:
Why Are These Foxes Tame? Maybe They Werent So Wild to Begin With - The New York Times

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium – BioSpace

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 10-14, 2019 in San Antonio, Tx.

"We are excited to present new data from several studies at SABCS this year, said Nicole Lambert, president of Myriad Oncology. "Our data represents Myriads commitment to advancing precision oncology for people with breast cancer and improving outcomes.

A list of the companys presentations at SABCS is below. Please visit Myriad at booth #113 to learn more about our portfolio of genetic tests for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news by using the hashtag #SABCS19.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About EndoPredictEndoPredict is a second-generation, prognostic test that aids personalized treatment planning for patients with early-stage breast cancer. EndoPredict has been validated in over 3500 patients with node-negative and node-positive disease and is the leading breast prognostic in Europe. In contrast to first-generation multigene prognostic tests, EndoPredict incorporates a 12-gene molecular score with known prognostic factors tumor size and nodal status. In clinical studies, EndoPredict demonstrated its robust ability to predict recurrence risk across multiple time-periods: 0-5, 5-10, and 5-15 years. EndoPredict provides clinically actionable information to physicians and patients as they consider the use of adjuvant chemotherapy and extended endocrine therapy.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys data across multiple genetic tests being featured at the 2019 San Antonio Breast Cancer Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

More:
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium - BioSpace